WA1
ACAD icon

Wimmer Associates 1’s Acadia Pharmaceuticals ACAD Stock Holding History

Wimmer Associates 1’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,850
Closed -$209K – 110
2015
Q4 		$209K Buy
+5,850
New +$206K 0.22% 93

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wimmer Associates 1's ACAD Position: Q1 2016 in Review

Wimmer Associates 1 sold out of Acadia Pharmaceuticals (ACAD) in Q1 2016, closing a stake of 5,850 shares — an estimated $209K sold.

Wimmer Associates 1 first reported a position in ACAD in Q4 2015 and held it in 1 quarter. The position peaked at $209K in Q4 2015. 212 funds tracked by Wall St. Rank hold ACAD as of Q1 2016.

  • Wimmer Associates 1 reported no remaining Acadia Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Wimmer Associates 1 sold 5,850 Acadia Pharmaceuticals shares in Q1 2016, an estimated $209K.
  • Wimmer Associates 1 first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Wimmer Associates 1's Acadia Pharmaceuticals position peaked at $209K in Q4 2015.
  • 212 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2016.

Based on Wimmer Associates 1's 13F filing for Q1 2016, filed 16 May 2016.